Changes in angiotensin-converting enzyme activity in lungs damaged by the pyrrolizidine alkaloid monocrotaline.
Administration of monocrotaline, a pyrrolizidine alkaloid, to male Sprague-Dawley rats for up to three weeks increased dry lung weights by 64% and reduced the specific activity of lung angiotensin-converting enzyme activity by 64%. When the total activity per lung is calculated, however, there is no significant difference between control and monocrotaline-treated animals. The decrease in specific activity is due to increase in total lung protein (52% above control) and not to an actual reduction in the total angiotensin-converting enzyme activity in th lung.
D000818:Animals; D008168:Lung / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D016686:Monocrotaline; D009929:Organ Size / Q000187:drug effects; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D011506:Proteins / Q000378:metabolism; D011763:Pyrrolizidine Alkaloids / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D011506:Proteins; D011763:Pyrrolizidine Alkaloids; D016686:Monocrotaline; D007703:Peptidyl-Dipeptidase A